https://www.selleckchem.com/products/4sc-202.html
MI and stroke in adults at very high or high cardiovascular risk who are receiving maximally tolerated statin therapy or are statin-intolerant, but not in those with moderate and low cardiovascular risk. Ezetimibe or PCSK9 inhibitors may reduce non-fatal MI and stroke in adults at very high or high cardiovascular risk who are receiving maximally tolerated statin therapy or are statin-intolerant, but not in those with moderate and low cardiovascular risk. In adults with low density lipoprotein (LDL) cholesterol levels 1.8 mmol/L (>
Like
Comment
Share
